Tetrahedron 69 (2013) 1427-1433

Contents lists available at SciVerse ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

Efficient one-pot synthesis of substituted pyrazoles

Meng Tang^{a,*}, Fu-Min Zhang^{b,*}

^a School of Pharmacy, Lanzhou University, Lanzhou 730000, PR China ^b State Key Laboratory of Applied Organic Chemistry, Lanzhou University, Lanzhou 730000, PR China

ARTICLE INFO

ABSTRACT

Article history: Received 17 September 2012 Received in revised form 31 October 2012 Accepted 14 December 2012 Available online 21 December 2012

Keywords. Substituted pyrazoles Regioselectivity Synthesis

1. Introduction

Pyrazoles and their derivatives represent an important class of compounds that are used extensively in the pharmaceutical and agrochemical industries.¹ Compounds containing the pyrazole moiety have a wide range of biological activities, such as the HIV-1 reverse transcriptase inhibitor PNU-32945,² cyclooxygenase-2 (COX-2) inhibitor Celecoxib,³ herbicide Fluazolate,^{1b} and fungicide Pyraclostrobin⁴ (Fig. 1). One of the most important methods for constructing pyrazole

rings^{5,6} is the classical Knorr pyrazole synthesis.⁷ The Knorr synthesis suffers from a regioselectivity issue,⁸ which arise for pyrazoles with $R^3 \neq R^5$. When considering the sizes of the substituents, Knorr synthesis products typically have R⁵ larger than R³ (Scheme 1a), such as in PNU-32945 and Celecoxib. To prepare a product with R³ larger than R⁵, such as Fluazolate and Pyraclostrobin, this method is usually unsuitable. Therefore, a general and convenient method for synthesis of pyrazoles with $R^3 > R^5$ is required.

2. Results and discussion

In the course of our study on the synthesis of substituted allenes from enones,⁹ we found that when using inorganic Brønsted bases, the reaction led to a different product, which was 1*H*-pyrazoles **A** and/or B (Scheme 2). This kind of transformation has been reported several times,¹⁰ however, to the best of our knowledge, this method

CI SO₂NH₂ ĊO₂C₃H₇ Fluazolate CN Celecoxib PNU-32945 H₃CO₂C

Pyraclostrobin

Fig. 1. Representative pyrazole derivatives.

has not been widely used in pyrazole synthesis. It is well known that under basic conditions, tautomerism between 1H-pyrazoles A and **B** occurs easily. Therefore, we investigated sequential synthesis of 1-position substituted pyrazoles by combining several elementary steps. Here, we report a three-step, one-pot synthesis of 1-position substituted pyrazole derivatives from readily available and simple starting materials, such as enones, *p*-toluenesulfonyl hydrazide (TsNHNH₂) and halides (R^1-X) (Scheme 1b).





Tetrahedror


C

An efficient, one-pot synthesis of substituted pyrazoles from enones, hydrazides, and halides was developed. In comparison with the classical Knorr pyrazole synthesis, this methodology gave a different type of product ($R^3 \ge R^5$). A range of substituted pyrazoles were prepared in good to high yields with complete regioselectivity.


© 2012 Elsevier Ltd. All rights reserved.

Corresponding authors. E-mail addresses: tangmeng@lzu.edu.cn (M. Tang), zhangfm@lzu.edu.cn (F.-M. Zhang).

^{0040-4020/\$ -} see front matter © 2012 Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.tet.2012.12.038



Scheme 1. Regioselectivity in the construction of pyrazole rings.




Scheme 2. $\alpha_n\beta$ -Unsaturated tosylhydrazones as versatile synthetic intermediates lead to allenes or pyrazoles.


Encouraged by previous results,⁹ our study was performed with cinnamaldehyde (1a) as a model substrate and NaOH as the base in EtOH (Table 1). First, trapping of the intermediate 5-phenyl-1Hpyrazole $(\mathbf{3})^{11}$ with benzyl bromide was attempted. The progress of pyrazole **3** formation was monitored by TLC, and when complete, NaOH and benzyl bromide were added. Under basic conditions, deprotonation of the NH moiety and rapid tautomerism resulted in **3a** and/or **3b**. Then **4a** was obtained by a nucleophilic substitution reaction of 3b with benzyl bromide. The structure of 4a was unambiguously established by NMR and single-crystal X-ray analysis (Fig. 2). However, the reaction of pyrazole 3 with benzyl bromide was quite slow, and the yield was only 44% after two days (entry 1, Table 1). Of the solvents screened, acetonitrile gave an excellent yield within 2 h (91%, entry 2, Table 1). We then investigated the scope of R¹–X, and found benzoyl chloride, iodoethane, allyl bromide, and propargyl bromide all gave the corresponding pyrazole derivatives (4b-e) in good to high yields (entries 3-6, Table 1). The reaction showed consistent, complete regioselectivity, with only single isomers obtained in all reactions. This regioselectivity could be a result of repulsion between the phenyl substituent and R¹.

Syntheses of a variety of pyrazoles were attempted to investigate the scope of the method. As shown in Table 2, different di-, tri- and tetrasubstituted pyrazole derivatives were obtained in good yields. However, the substituent R^5 apparently affected the formation of tosylhydrazone. Compared with benzalacetone (**1e**) as the substrate, tosylhydrazone production was very slow in aceto-nitrile with chalcone (**1d**) and **1f** as substrates (entries 9–13, 16, 17, Table 2). EtOH was used in the initial stage of the reaction, and after the pyrazole formed, it was removed under reduced pressure and acetonitrile was used to complete the procedure. When **1e** was used as the substrate, the bulk of R^1 apparently affected the regioselectivity of the reaction, benzyl bromide and benzoyl chloride could trap the intermediate 1*H*-pyrazole with complete

Table 1

One-pot synthesis of 1,3-disubstituted pyrazoles and the scope of the halides





^a The yields are for the isolated product.

^b 5-Phenyl-1*H*-pyrazole **3** was isolated in 51% yield.

regioselectivity, and only one product (**4s** or **4t**) was isolated, (entries 14, 15, Table 2) however, iodoethane gave a disappointing result, and the ratio of **4v:4w**¹² was 2.2:1 (Scheme 3). Moreover, substrates **1e** and **1f** led to the same product **4s** or **4t** when trapped with benzyl bromide or benzoyl chloride (entries 14–17, Table 2).







Table 2	
Preparation of substituted pyrazoles	5

Entry	Enone 1	R ¹ -X	Product	Yield ^a (%)	Entry	Enone 1	R ¹ -X	Product	Yield ^a (%)
1	Ph H 1b	Ph Br	Ph N-N Ph 4f	88	10	1d	O Ph Cl	Ph Ph 40	85
2	1b	O Ph Cl	Ph Ph 4g	89	11	1d		Ph 4p	98
3	1b		N-N Ph 4h	93	12	1d	Br	Ph 4q	96
4	1b	Br	N-N Ph _{4i}	89	13	1d	Br	Ph 4r	74
5	16	Br	N-N Ph 4j	82	14	Ph 1e	Ph Br	Ph Ph 4s	78
6	Ph H Ic	Ph Br	Ph Ph 4k	94	15	1e	O Ph Cl	Ph Ph 4t	76
7	1c	O Ph Cl	Ph 4	95	16	O Ph 1f	O Ph Cl	Ph Ph 4t	73
8	1c	≫∽ _{Br}	N-N II Ph 4m	78	17	1f	Ph Br	Ph Ph 4s	65
9	Ph Id	Ph [^] Br	Ph Ph 4n	89	18	Ph 1g	Ph CI	Ph Ph 4u	73

^a The yields are for the isolated product.



Scheme 3. Regioselectivity in preparation of 1,3,5-trisubstituted pyrazoles.

3. Conclusions

In conclusion, an efficient, one-pot, three-step synthesis of substituted pyrazoles was developed. A series of 1,3-disubstituted, 1,4-disubstituted, 1,3,4-trisubstituted, 1,3,5-trisubstituted and 1,3,4,5-tetrasubstituted pyrazole derivatives were synthesized in good yields. This efficient and highly modular one-pot procedure is practical and useful. Further studies on the biological activities of the products and application of this methodology to other interesting pyrazole derivatives are underway in our laboratory.

4. Experimental section

4.1. General remarks

For product purification by flash column chromatography, silica gel (200–300 mesh) and light petroleum ether (bp 60–90 °C) are used. All organic extracts were dried over anhydrous MgSO₄. IR spectra were recorded on a Nicolet FT-170SX spectrometer. ¹H and ¹³C NMR spectra were taken on a Bruker AVANCE III 400 MHz spectrometer with TMS as an internal standard and CDCl₃ as solvent. The HRMS data were determined on a Bruker Daltonics APEXII 47e FT-ICR spectrometer.

4.2. Typical representative procedure for the synthesis 1-benzyl-3-phenyl-1*H*-pyrazole (4a)

A mixture of **1a** (132 mg, 1.0 mmol) and TsNHNH₂ (205 mg, 1.1 mmol) in CH₃CN (2 mL) were stirred at room temperature for 3 h and then CH₃CN (2 mL), NaOH (44 mg, 1.1 mmol) were added and the mixture was heated at reflux for 15 h, then NaOH (60 mg, 1.5 mmol) and benzyl bromide (255 mg, 1.5 mmol) were subsequently added and the mixture was stirred at room temperature for 2 h. The product was extracted with Et₂O and the organic layer was washed with brine, dried over anhydrous MgSO₄, filtered, and concentrated in vacuo. Purification by chromatography on silica gel afforded the desired product 4a as a white crystalline solid (213 mg, 91%). Mp 60–62 °C; $\delta_{\rm H}$ (400 MHz, CDCl₃) 5.32 (2H, s), 6.55 (1H, d, J 2.4 Hz), 7.20-7.23 (2H, m), 7.25-7.33 (5H, m), 7.35-7.39 (2H, m), 7.81–7.82 (2H, m); δ_C (100 MHz, CDCl₃) 56.0, 103.2, 125.6, 127.5, 127.6, 127.9, 128.5, 128.7, 130.5, 133.5, 136.6, 151.5; HRMS (ESI): MH⁺, found 235.1232. $C_{16}H_{15}N_2$ requires 235.1230, ν_{max} (liquid film) 3126, 3107, 3062, 3033, 2936, 1498, 1455, 1078 cm⁻

4.2.1. Preparation of phenyl(3-phenyl-1H-pyrazol-1-yl)methanone (**4b**). Compound **4b** (221 mg, 89%) was prepared following the procedure described for **4a** by using **1a** (132 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and benzoyl chloride (210 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 6.84 (1H, d, *J* 2.8 Hz), 7.35–7.44 (3H, m), 7.49–7.53 (2H, m), 7.59–7.63 (1H, m), 7.85–7.88 (2H, m), 8.24–8.27 (2H, m), 8.45 (1H, d, *J* 2.8 Hz); $\delta_{\rm C}$ (100 MHz, CDCl₃) 107.1, 126.4, 128.0, 128.7, 129.1, 131.5, 131.7, 131.78, 131.84, 132.9, 155.9, 166.0; HRMS (ESI): MNa⁺, found: 271.0838. C₁₆H₁₂N₂ONa requires 271.0842; $\nu_{\rm max}$ (liquid film) 3150, 3125, 3062, 1697, 1541, 1451, 1403, 1351, 1275 cm⁻¹.

4.2.2. Preparation of 1-ethyl-3-phenyl-1H-pyrazole (**4c**). Compound **4c** (150 mg, 87%) was prepared following the procedure described

for **4a** by using **1a** (132 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and iodoethane (234 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 1.48 (3H, t, *J* 7.6 Hz), 4.17 (2H, q, *J* 7.6 Hz), 6.51 (1H, d, *J* 2.0 Hz), 7.26 (1H, t, *J* 7.2 Hz), 7.36–7.39 (3H, m), 7.80 (2H, d, *J* 7.2 Hz); $\delta_{\rm C}$ (100 MHz, CDCl₃) 15.6, 47.0, 102.5, 125.5, 127.3, 128.5, 129.4, 133.7, 151.1; HRMS (ESI): MH⁺, found: 173.1070. C₁₁H₁₃N₂ requires 173.1073; $\nu_{\rm max}$ (liquid film) 3063, 3035, 2982, 2939, 1605, 1500, 1457, 1352, 1225 cm⁻¹.

4.2.3. Preparation of 1-allyl-3-phenyl-1H-pyrazole (**4d**). Compound **4d** (158 mg, 86%) was prepared following the procedure described for **4a** by using **1a** (132 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and allyl bromide (180 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 4.75 (2H, dt, J 5.6, 1.2 Hz), 5.17–5.26 (2H, m), 5.99–6.08 (1H, m), 6.55 (1H, d, J 2.4 Hz), 7.25–7.29 (1H, m), 7.35–7.39 (3H, m), 7.79–7.81 (2H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 54.7, 102.9, 118.4, 125.5, 127.4, 128.5, 130.1, 132.9, 133.5, 151.4; HRMS (ESI): MH⁺, found: 185.1070. C₁₂H₁₃N₂ requires 185.1073; $\nu_{\rm max}$ (liquid film) 3066, 3035, 2985, 2925, 1500, 1458, 1355, 1327, 1226, 1074 cm⁻¹.

4.2.4. Preparation of 3-phenyl-1-(prop-2-yn-1-yl)-1H-pyrazole (**4e**). Compound **4e** (129 mg, 71%) was prepared following the procedure described for **4a** by using **1a** (132 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and propargyl bromide (177 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 2.49 (1H, t, *J* 2.8 Hz), 4.95 (2H, d, *J* 2.8 Hz), 6.57 (1H, d, *J* 2.4 Hz), 7.26–7.30 (1H, m), 7.36–7.39 (2H, m), 7.60 (1H, d, *J* 2.4 Hz), 7.78 (2H, dd, *J* 8.0, 1.2 Hz); $\delta_{\rm C}$ (100 MHz, CDCl₃) 41.5, 74.7, 76.7, 103.3, 125.6, 127.7, 128.5, 130.0, 133.2, 152.0; HRMS (ESI): MH⁺, found: 183.0919. C₁₂H₁₁N₂ requires 183.0917; $\nu_{\rm max}$ (liquid film) 3290, 3063, 3037, 2925, 2127, 1500, 1459, 1337, 1227 cm⁻¹.

4.3. Typical representative procedure for the synthesis 1,4-dibenzyl-1*H*-pyrazole (4f)

A mixture of 2-benzylacrylaldehyde (**1b**)¹³ (146 mg, 1.0 mmol) and TsNHNH₂ (205 mg, 1.1 mmol) in CH₃CN (2 mL) were stirred at room temperature for 2 h and then CH₃CN (2 mL), NaOH (44 mg, 1.1 mmol) were added and the mixture was heated at reflux for 15 h, then NaOH (60 mg, 1.5 mmol) and benzyl bromide (255 mg, 1.5 mmol) were subsequently added and the mixture was stirred at room temperature for 2 h. The product was extracted with Et₂O and the organic layer was washed with brine, dried over anhydrous MgSO₄, filtered, and concentrated in vacuo. Purification by chromatography on silica gel afforded the desired product 4f as colorless oil (218 mg, 88%). $\delta_{\rm H}$ (400 MHz, CDCl₃) 3.79 (2H, s), 5.21 (2H, s), 7.11 (1H, s), 7.17–7.21 (5H, m), 7.24–7.33 (5H, m), 7.37 (1H, s); δ_C (100 MHz, CDCl₃) 30.6, 55.9, 121.0, 126.0, 127.5, 127.9, 128.0, 128.36, 128.39, 128.7, 136.7, 139.3, 141.0; HRMS (ESI): MH⁺, found 249.1381. C₁₇H₁₇N₂ requires 249.1386, *v*_{max} (liquid film) 3061, 3028, 2922, 2848, 1494, 1450, 1396, 1152 cm⁻

4.3.1. Preparation of (4-benzyl-1H-pyrazol-1-yl)(phenyl)methanone (**4g**). Compound **4g** (233 mg, 89%) was prepared following the procedure described for **4f** by using **1b** (146 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and benzoyl chloride (210 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 3.88 (2H, s), 7.22–7.26 (3H, m), 7.31–7.34 (2H, m), 7.45–7.50 (2H, m), 7.56–7.61 (1H, m), 7.63 (1H, s), 8.06–8.08 (2H, m), 8.16 (1H, d, *J* 0.4 Hz); $\delta_{\rm C}$ (100 MHz, CDCl₃) 30.5, 124.8, 126.6, 128.0, 128.3, 128.5, 128.7, 131.3, 131.6, 132.8, 139.3, 145.2, 166.3; HRMS (ESI): MNa⁺, found: 285.1002. C₁₇H₁₄N₂ONa requires 285.0998; $\nu_{\rm max}$ (liquid film) 3062, 3028, 2919, 2850, 1697, 1365, 1244 cm⁻¹.

4.3.2. Preparation of 4-benzyl-1-ethyl-1H-pyrazole (**4h**). Compound **4h** (173 mg, 93%) was prepared following the procedure described

for **4f** by using **1b** (146 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and iodoethane (234 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 1.44 (3H, t, *J* 7.2 Hz), 3.81 (2H, s), 4.09 (2H, q, *J* 7.2 Hz), 7.12 (1H, s), 7.17–7.21 (3H, m), 7.24–7.30 (2H, m), 7.33 (1H, s); $\delta_{\rm C}$ (100 MHz, CDCl₃) 15.5, 30.6, 46.8, 120.4, 126.0, 127.0, 128.37, 128.43, 138.7, 141.2; HRMS (ESI): MH⁺, found: 187.1237. C₁₂H₁₅N₂ requires 187.1230; $\nu_{\rm max}$ (liquid film) 3082, 3061, 3026, 2981, 2934, 1494, 1449, 1397, 1356, 1157 cm⁻¹.

4.3.3. Preparation of 1-allyl-4-benzyl-1H-pyrazole (**4i**). Compound **4i** (176 mg, 89%) was prepared following the procedure described for **4f** by using **1b** (146 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and allyl bromide (180 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 3.81 (2H, s), 4.66 (2H, dt, *J* 6.0, 1.2 Hz), 5.15–5.24 (2H, m), 5.94–6.04 (1H, m), 7.13 (1H, s), 7.17–7.20 (3H, m), 7.24–7.29 (2H, m), 7.35 (1H, s); $\delta_{\rm C}$ (100 MHz, CDCl₃) 3.06, 54.6, 118.3, 120.8, 126.0, 127.7, 128.37, 128.39, 133.0, 139.1, 141.1; HRMS (ESI): MH⁺, found: 199.1232. C₁₃H₁₅N₂ requires 199.1230; $\nu_{\rm max}$ (liquid film) 3083, 3026, 2919, 2849, 1494, 1446, 1397, 1328, 1152 cm⁻¹.

4.3.4. Preparation of 4-benzyl-1-(prop-2-yn-1-yl)-1H-pyrazole (**4j**). Compound **4j** (161 mg, 82%) was prepared following the procedure described for **4f** by using **1b** (146 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and propargyl bromide (177 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 2.45 (1H, t, *J* 2.4 Hz), 3.81 (2H, s), 4.85 (2H, d, *J* 2.4 Hz), 7.18–7.21 (3H, m), 7.24–7.30 (2H, m), 7.33–7.35 (2H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 30.5, 41.4, 74.4, 76.9, 121.3, 126.1, 127.5, 128.4, 139.8, 140.8; HRMS (ESI): MH⁺, found: 197.1074. C₁₃H₁₃N₂ requires 197.1073; $\nu_{\rm max}$ (liquid film) 3289, 3084, 3061, 3027, 2916, 2126, 1602, 1494, 1446, 1395, 1349, 1152 cm⁻¹.

4.4. Typical representative procedure for the synthesis 1-benzyl-4-methyl-3-phenyl-1*H*-pyrazole (4k)

A mixture of (E)-2-methyl-3-phenylacrylaldehyde (1c) (146 mg, 1.0 mmol) and TsNHNH₂ (205 mg, 1.1 mmol) in CH₃CN (2 mL) were stirred at room temperature for 3 h and then CH₃CN (2 mL), NaOH (44 mg, 1.1 mmol) were added and the mixture was heated at reflux for 15 h, then NaOH (60 mg, 1.5 mmol) and benzyl bromide (255 mg, 1.5 mmol) were subsequently added and the mixture was stirred at room temperature for 2 h. The product was extracted with Et₂O and the organic layer was washed with brine, dried over anhydrous MgSO₄, filtered, and concentrated in vacuo. Purification by chromatography on silica gel afforded the desired product 4k as colorless oil (233 mg, 94%). δ_H (400 MHz, CDCl₃) 2.20 (3H, s), 5.27 (2H, s), 7.15 (1H, s), 7.21-7.35 (6H, m), 7.38-7.42 (2H, m), 7.69-7.71 (2H, m); δ_C (100 MHz, CDCl₃) 10.1, 55.9, 114.2, 127.1, 127.4, 127.7, 127.9, 128.3, 128.7, 129.7, 134.1, 136.8, 149.7; HRMS (ESI): MH⁺, found 249.1380. C₁₇H₁₇N₂ requires 249.1386, *v*_{max} (liquid film) 3061, $3030, 2926, 2867, 1603, 1552, 1496, 1444, 1343, 1162 \text{ cm}^{-1}$.

4.4.1. Preparation of (4-methyl-3-phenyl-1H-pyrazol-1-yl)(phenyl) methanone (**4l**). Compound **4l** (249 mg, 95%) was prepared following the procedure described for **4k** by using **1c** (146 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and benzoyl chloride (210 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 2.31 (3H, s), 7.37–7.51 (5H, m), 7.58 (1H, t, *J* 7.2 Hz), 7.75 (2H, d, *J* 7.2 Hz), 8.21–8.25 (3H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 10.4, 118.8, 127.8, 128.0, 128.5, 128.6, 130.0, 131.67, 131.72, 132.5, 132.7, 155.5, 165.9; HRMS (ESI): MNa⁺, found: 285.0997. C₁₇H₁₄N₂ONa requires 285.0998; $\nu_{\rm max}$ (liquid film) 3061, 3030, 2925, 2867, 1603, 1552, 1495, 1447, 1343, 1162 cm⁻¹.

4.4.2. Preparation of 1-allyl-4-methyl-3-phenyl-1H-pyrazole (**4m**). Compound **4m** (155 mg, 78%) was prepared following the

procedure described for **4k** by using **1c** (146 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and allyl bromide (180 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 2.22 (3H, d, *J* 0.8 Hz), 4.71 (2H, dt, *J* 4.4, 1.2 Hz), 5.20–5.25 (2H, m), 5.99–6.09 (1H, m), 7.21 (1H, s), 7.27–7.31 (1H, m), 7.37–7.41 (2H, m), 7.67–7.69 (2H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 10.0, 54.5, 113.9, 118.3, 127.0, 127.4, 128.3, 129.4, 133.1, 134.1, 149.7; HRMS (ESI): MH⁺, found: 199.1232. C₁₃H₁₅N₂ requires 199.1230; $\nu_{\rm max}$ (liquid film) 3062, 3024, 2922, 2868, 1604, 1552, 1438, 1340, 1165 cm⁻¹.

4.5. Typical representative procedure for the synthesis 1-benzyl-3,5-diphenyl-1*H*-pyrazole (4n)

A mixture of chalcone (1d) (208 mg, 1.0 mmol) and TsNHNH₂ (205 mg, 1.1 mmol) in EtOH (2 mL) were stirred at room temperature for 48 h and then EtOH (2 mL), NaOH (44.0 mg, 1.1 mmol) were added and the mixture was heated at reflux for 15 h, then the solvent was removed under reduced pressure, then CH₃CN (4 mL), NaOH (60 mg, 1.5 mmol) and benzyl bromide (255 mg, 1.5 mmol) were subsequently added and the mixture was stirred at room temperature for 2 h. The product was extracted with Et₂O and the organic layer was washed with brine, dried over anhydrous MgSO₄, filtered, and concentrated in vacuo. Purification by chromatography on silica gel afforded the desired product **4n** as white crystalline solid (276 mg, 89% yield). Mp 114–117 °C; $\delta_{\rm H}$ (400 MHz, CDCl₃) 5.38 (2H, s), 6.66 (1H, s), 7.09 (2H, d, J 7.2 Hz), 7.21-7.30 (4H, m), 7.32–7.42 (7H, m), 7.87 (2H, d, / 7.2 Hz); δ_{C} (100 MHz, CDCl₃) 53.2, 103.7, 125.6, 126.7, 127.4, 127.6, 128.55, 128.56, 128.6, 128.8, 130.6, 133.4, 137.7, 145.4, 150.9; HRMS (ESI): MH⁺, found 311.1536. C₂₂H₁₉N₂ requires 311.1543, v_{max} (liquid film) 3060, 2955, 2924, 2853, 1452, 1361, 1307 cm⁻¹.

4.5.1. Preparation of (3,5-diphenyl-1H-pyrazol-1-yl)(phenyl)methanone (**4o**). Compound **4o** (276 mg, 85%) was prepared following the procedure described for **4n** by using **1d** (208 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and benzoyl chloride (210 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 6.86 (1H, s), 7.35–7.44 (6H, m), 7.47–7.51 (4H, m), 7.59–7.63 (1H, m), 7.86 (2H, dd, *J* 8.0, 1.2 Hz), 8.11–8.13 (2H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 108.9, 126.3, 128.0, 128.2, 128.5, 128.7, 129.1, 130.8, 131.8, 131.9, 132.5, 133.1, 148.6, 153.5, 167.4; HRMS (ESI): MNa⁺, found: 347.1158. C₂₂H₁₆N₂ONa requires 347.1155; $\nu_{\rm max}$ (liquid film) 3061, 2924, 2856, 1709, 1560, 1488, 1453, 1331, 1305 cm⁻¹.

4.5.2. Preparation of 1-ethyl-3,5-diphenyl-1H-pyrazole (**4p**). Compound **4p** (243 mg, 98%) was prepared following the procedure described for **4n** by using **1d** (208 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and iodoethane (234 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 1.44 (3H, t, *J* 7.2 Hz), 4.20 (2H, q, *J* 7.2 Hz), 6.57 (1H, s), 7.29 (1H, t, *J* 7.6 Hz), 7.38–7.48 (7H, m), 7.84–7.86 (2H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 15.9, 44.6, 103.3, 125.6, 127.5, 128.48, 128.54, 128.7, 128.8, 130.9, 133.6, 144.4, 150.5; HRMS (ESI): MH⁺, found: 249.1384. C₁₇H₁₇N₂ requires 249.1386; $\nu_{\rm max}$ (liquid film) 3060, 2976, 2937, 1605, 1548, 1481, 1460, 1373, 1304 cm⁻¹.

4.5.3. Preparation of 1-allyl-3,5-diphenyl-1H-pyrazole (**4q**). Compound **4q** (250 mg, 96%) was prepared following the procedure described for **4n** by using **1d** (208 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and allyl bromide (180 mg, 1.5 mmol) as colorless oil. $\delta_{\rm H}$ (400 MHz, CDCl₃) 4.77 (2H, dd, *J* 3.2, 1.6 Hz), 5.03 (1H, dd, *J* 16.8, 1.2 Hz), 5.20 (1H, dd, *J* 10.4, 1.2 Hz), 6.00–6.09 (1H, m), 6.61 (1H, s), 7.29 (1H, t, *J* 7.6 Hz), 7.37–7.46 (7H, m), 7.84–7.86 (2H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 52.0, 103.3, 117.2, 125.6, 127.6, 128.52, 128.56, 128.59, 128.7, 130.6, 133.4, 133.8, 145.1, 150.9; HRMS (ESI): MH⁺, found: 261.1385. C₁₈H₁₇N₂ requires 261.1386; ν_{max} (liquid film) 3062, 2986, 2928, 1605, 1549, 1483, 1459, 1438, 1367, 1304 cm⁻¹.

4.5.4. Preparation of 3,5-diphenyl-1-(prop-2-yn-1-yl)-1H-pyrazole (**4r**). Compound **4r** (191 mg, 74%) was prepared following the procedure described for **4n** by using **1d** (208 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol) and propargyl bromide (177 mg, 1.5 mmol) as white crystalline solid. Mp 93–95 °C; $\delta_{\rm H}$ (400 MHz, CDCl₃) 2.42 (1H, t, *J* 2.4 Hz), 4.90 (2H, d, *J* 2.4 Hz), 6.62 (1H, s), 7.28–7.32 (1H, m), 7.38–7.50 (5H, m), 7.55–7.58 (2H, m), 7.84–7.86 (2H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 39.7, 73.6, 78.4, 103.7, 125.7, 127.8, 128.5, 128.7, 128.8, 130.1, 133.1, 145.0, 151.4; HRMS (ESI): MH⁺, found: 259.1223. C₁₈H₁₅N₂ requires 259.1230; $\nu_{\rm max}$ (liquid film) 3294, 3063, 2963, 2932, 1482, 1458, 1432 cm⁻¹.

4.6. Typical representative procedure for the synthesis 1-benzyl-5-methyl-3-phenyl-1*H*-pyrazole (4s)

A mixture of (E)-4-phenylbut-3-en-2-one (1e) (146 mg, 1.0 mmol) and TsNHNH₂ (205 mg, 1.1 mmol) in CH₃CN (2 mL) were stirred at room temperature for 3 h and then CH₃CN (2 mL), NaOH (44 mg, 1.1 mmol) were added and the mixture was heated at reflux for 17 h, then NaOH (60 mg, 1.5 mmol) and benzyl bromide (255 mg, 1.5 mmol) were subsequently added and the mixture was stirred at room temperature for 2 h. The product was extracted with Et₂O and the organic layer was washed with brine, dried over anhydrous MgSO₄, filtered, and concentrated in vacuo. Purification by chromatography on silica gel afforded the desired product 4s as white crystalline solid (194 mg, 78% yield). Mp 86–87 °C; $\delta_{\rm H}$ (400 MHz, CDCl₃) 2.18 (3H, s), 5.32 (2H, s), 6.37 (1H, s), 7.11 (2H, d, J 6.8 Hz), 7.22–7.31 (4H, m), 7.36–7.39 (2H, m), 7.80–7.82 (2H, m); δ_{C} (100 MHz, CDCl₃) 11.2, 53.1, 103.2, 125.5, 126.6, 127.4, 127.5, 128.5, 128.6, 133.7, 137.0, 139.8, 150.3; HRMS (ESI): MH⁺, found 249.1385. C₁₇H₁₇N₂ requires 249.1386, *v*_{max} (liquid film) 3063, 3027, 2914, 1547, 1480, 1451, 1427, 1310 cm $^{-1}$.

4.6.1. Preparation of (5-methyl-3-phenyl-1H-pyrazol-1-yl)(phenyl) methanone (**4t**). Compound **4t** (199 mg, 76%) was prepared following the procedure described for **4s** by using **1e** (146 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and benzoyl chloride (210 mg, 1.5 mmol) as white crystalline solid. Mp 81–83 °C; $\delta_{\rm H}$ (400 MHz, CDCl₃) 2.72 (3H, d, J 0.8 Hz), 6.57 (1H, d, J 0.8 Hz), 7.23–7.41 (3H, m), 7.46–7.50 (2H, m), 7.56–7.60 (1H, m), 7.78–7.81 (2H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 14.5, 107.9, 126.2, 127.8, 128.6, 128.9, 131.7, 132.0, 132.5, 133.1, 145.7, 153.4, 168.5; HRMS (ESI): MNa⁺, found: 285.0991. C₁₇H₁₄N₂ONa requires 285.0998; $\nu_{\rm max}$ (liquid film) 3112, 3061, 3031, 2970, 2925, 1690, 1597, 1577, 1469, 1446, 1349 cm⁻¹.

4.6.2. Preparation of 1-ethyl-5-methyl-3-phenyl-1H-pyrazole (**4v**) and 1-ethyl-3-methyl-5-phenyl-1H-pyrazole (**4w**). Compound **4v** (123 mg, 66%) and **4w** (56 mg, 30%) were prepared following the procedure described for **4s** by using **1e** (146 mg, 1.0 mmol), TsNHNH₂ (205 mg, 1.1 mmol), NaOH (104 mg, 2.6 mmol), and iodoethane (234 mg, 1.5 mmol) as colorless oil. For **4v**: $\delta_{\rm H}$ (400 MHz, CDCl₃) 1.43 (3H, t, *J* 7.2 Hz), 2.29 (3H, s), 4.12 (2H, q, *J* 7.2 Hz), 6.29 (1H, s), 7.24–7.27 (1H, m), 7.34–7.38 (2H, m), 7.75–7.77 (2H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 11.0, 15.5, 44.0, 102.6, 125.4, 127.2, 128.4, 133.9, 138.7, 150.0; HRMS (ESI): MH⁺, found: 187.1225. C₁₂H₁₅N₂ requires 187.1320; $\nu_{\rm max}$ (liquid film) 3059, 2980, 2938, 2875, 1550, 1444, 1372, 1315 cm⁻¹. For **4w**: $\delta_{\rm H}$ (400 MHz, CDCl₃) 1.39 (3H, t, *J* 7.2 Hz), 2.32 (3H, s), 4.09 (2H, q, *J* 7.2 Hz), 6.05 (1H, s), 7.36–7.46 (5H, m); $\delta_{\rm C}$ (100 MHz, CDCl₃) 13.5, 15.9, 44.1, 105.6, 128.3, 128.6, 128.7, 131.2, 143.9, 147.7; HRMS (ESI): MH⁺, found: 187.1227. C₁₂H₁₅N₂ requires

187.1320; $\nu_{\rm max}$ (liquid film) 3059, 2976, 2932, 2876, 1548, 1495, 1453, 1423, 1379 cm $^{-1}$.

4.7. Procedure for the synthesis (4,5-dimethyl-3-phenyl-1*H*-pyrazol-1-yl)(phenyl)methanone (4u)

A mixture of (*E*)-3-methyl-4-phenylbut-3-en-2-one (**1g**) (160 mg, 1.0 mmol) and TsNHNH₂ (205 mg, 1.1 mmol) in CH₃CN (2 mL) were stirred at room temperature for 24 h and then CH₃CN (2 mL), NaOH (44 mg, 1.1 mmol) were added and the mixture was heated at reflux for 24 h, then NaOH (60 mg, 1.5 mmol) and benzovl chloride (256 mg, 1.5 mmol) were subsequently added and the mixture was stirred at room temperature for 2 h. The product was extracted with Et₂O and the organic layer was washed with brine, dried over anhydrous MgSO₄, filtered, and concentrated in vacuo. Purification by chromatography on silica gel afforded the desired product 4u as white crystalline solid (202 mg, 73%). Mp 143–146 °C; $\delta_{\rm H}$ (400 MHz, CDCl₃) 2.17 (3H, s), 2.63 (3H, s), 7.33-7.46 (5H, m), 7.52-7.68 (1H, m), 7.67 (2H, d, J 7.2 Hz), 8.06 (2H, d, J 7.2 Hz); δ_C (100 MHz, CDCl₃) 9.2, 12.4, 116.5, 127.7, 128.1, 128.4, 131.5, 132.3, 132.9, 133.4, 141.5, 153.8, 168.5; HRMS (ESI): MNa⁺, found 299.1146. C₁₈H₁₆N₂ONa requires 299.1155, *v*_{max} (liquid film) 3061, 2960, 2925, 1694, 1450, 1338 cm⁻¹.

Acknowledgements

We are grateful for financial support from NSFC (Nos. 21002044) and the Fundamental Research Funds for the Central Universities (lzujbky-2012-89). We also acknowledge Prof. Yong-Qiang Tu and Prof. Chun-An Fan of Lanzhou University for their helpful discussions.

Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.tet.2012.12.038.

References and notes

- (a) Elguero, J. In Comprehensive Heterocyclic Chemistry; Katritzky, A. R., Rees, C. W., Scriven, E. F. V., Eds.; Pergamon: Oxford, 1996; Vol. 5; (b) Hirai, K.; Uchida, A.; Ohno, R. In Herbicide Classes in Development; Boger, P., Hirai, K., Wakabyashi, K., Eds.; Springer: Heidelberg, Germany, 2002; pp 179–289; (c) Elguero, J.; Goya, P.; Jagerovic, N.; Silva, A. M. S. Targets Heterocycl. Syst. 2002, 6, 52; (d) Seltzman, H. H. Drug Dev. Res. 2009, 70, 601; (e) Dai, H.-X.; Stepan, A. F.; Plummer, M. S.; Zhang, Y.-H.; Yu, J.-Q. J. Am. Chem. Soc. 2011, 133, 7222; (f) Jones, L. H.; Allan, G.; Corbau, R.; Midleton, D. S.; Mowbray, C. E.; Newman, S. D.; Phillips, C.; Webster, R.; Westby, M. Chem. Biol. Drug Des. 2011, 77, 393.
- Phillips, C.; Webster, R.; Westby, M. Chem. Biol. Drug Des. 2011, 77, 393.
 Genin, M. J.; Biles, C.; Keiser, B. J.; Poppe, S. M.; Swaney, S. M.; Tarpley, W. G.; Yagi, Y.; Romero, D. L. J. Med. Chem. 2000, 43, 1034.
- Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W. J. Med. Chem. 1997, 40, 1347.
- Mercader, J. V.; Suárez-Pantaleón, C.; Agulló, C.; Abad-Somovilla, A.; Abad-Fuentes, A. J. Agric. Food Chem. 2008, 56, 7682.
- For reviews, see: (a) Fustero, S.; Sánchez-Roselló, M.; Barrio, P.; Simón-Fuentes, A. Chem. Rev. 2011, 111, 6984; (b) Fustero, S.; Simón-Fuentes, A.; Sanz-Cervera, J. F. Org. Prep. Proced. Int. 2009, 41, 253; (c) Makino, K.; Kim, H. S.; Kurasawa, Y. J. Heterocycl. Chem. 1999, 36, 321; (d) Makino, K.; Kim, H. S.; Kurasawa, Y. J. Heterocycl. Chem. 1998, 35, 489.
- C. Recent examples about synthesis of pyrazole, see: (a) Kumar, R.; Namboothiri, I. N. N. Org. Lett. 2011, 13, 4016; (b) Zhu, Y.; Wen, S.; Yin, G.; Hong, D.; Lu, P.; Wang, Y. Org. Lett. 2011, 13, 3553; (c) Willy, B.; Müller, T. J. J. Org. Lett. 2011, 13, 2082; (d) Shan, G.; Liu, P.; Rao, Y. Org. Lett. 2011, 13, 1746; (e) Wang, Y.; Bi, X.; Li, W.-Q.; Li, D.; Zhang, Q.; Liu, Q.; Ondon, B. S. Org. Lett. 2011, 13, 1722; (f) Avila, B.; Solano, D. M.; Haddadin, M. J.; Kurth, M. J. Org. Lett. 2011, 13, 1722; (f) Avila, B.; Solano, D. M.; Haddadin, M. J.; Kurth, M. J. Org. Lett. 2011, 13, 1722; (f) Avila, B.; Solano, D. M.; Haddadin, M. J.; Kurth, M. J. Org. Lett. 2011, 13, 1722; (f) Avila, B.; Solano, D. M.; Haddadin, M. J.; Kurth, M. J. Org. Lett. 2011, 13, 1060; (g) Verma, D.; Mobin, S.; Namboothiri, I. N. N. J. Org. Chem. 2011, 76, 4764; (h) Surmont, R.; Verniest, G.; Schrijver, M. D.; Thuring, J. W.; Holte, P. t.; Deroose, F.; Kimpe, N. D. J. Org. Chem. 2011, 76, 4764; (i) Surmont, R.; Verniest, G.; Schrijver, M. D.; Thuring, J. W.; Holte, P. t.; Deroose, F.; Kimpe, N. D. J. Org. Lett. 2010, 12, 4924; (j) Okitsu, T.; Sato, K.; Wada, A. Org. Lett. 2010, 12, 3506; (k) Surmont, R.; Verniest, G.; Kimpe, N. D. Org. Lett. 2010, 12, 4648; (l) Delaunay, T.; Genix, P.; Es-Sayed, M.; Vors, J.-P.; Monteiro, N.; Balme, G. Org. Lett. 2010, 12, 3328; (m) Mohanan, K.; Martin, A. R.; Toupet, L.; Smietana, M.; Vasseur, J.-J. Angew. Chem., Int. Ed. 2010, 49, 3196; (n) Neumann, J. J.; Suri,

M.; Glorius, F. Angew. Chem., Int. Ed. **2010**, 49, 7790; (o) Cheng, X.; Ma, S. Chem. Commun. **2009**, 4263.

- (a) Gerstenberger, B. S.; Rauckhorst, M. R.; Starr, J. T. Org. Lett. 2009, 11, 2097; (b) Heller, S. T.; Natarajan, S. R. Org. Lett. 2006, 8, 2675; (c) Peruncheralathan, S.; Khan, T. A.; Ila, H.; Junjappa, H. J. Org. Chem. 2005, 70, 10030; (d) Patel, M. V.; Bell, R.; Majest, S.; Henry, R.; Kolasa, T. J. Org. Chem. 2004, 69, 7058; (e) Knorr, L. Ber. 1883, 16, 2587.
- (a) Norris, T.; Colon-Cruz, R.; Ripin, D. H. B. Org. Biomol. Chem. 2005, 3, 1844; (b) Silva, V. L. M.; Silva, A. M. S.; Pinto, D. C. G. A.; Cavaleiro, J. A. S.; Elguero, J. Eur. J. Org. Chem. 2004, 4348; (c) Bishop, B. C.; Brands, K. M. J.; Gibb, A. D.; Kennedy, D. J. Synthesis 2004, 434; (d) Miller, R. D.; Reiser, O. J. Heterocycl. Chem. 1993, 30, 755.
 Tang, M.; Fan, C.-A.; Zhang, F.-M.; Tu, Y.-Q.; Zhang, W.-X.; Wang, A.-X. Org. Lett.
- **2008**, *10*, 5585. 10. The behaviour of α,β -unsaturated tosylhydrazone towards bases has not been
- exhaustively examined. Isolated examples of cyclization to pyrazole isomers can be found in: (a) Closs, G. L.; Böll, W. A. Angew. Chem., Int. Ed. Engl. **1963**, 2, 399; (b)

Closs, G. L.; Closs, L. E.; Böll, W. A. J. Am. Chem. Soc. 1963, 85, 3796; (c) Sharp, J. T.; Findlay, R. H.; Thorogood, P. B. J. Chem. Soc., Perkin Trans. 1 1975, 102; (d) Almirante, N.; Cerri, A.; Fedrizzi, G.; Marazzi, G.; Santagostino, M. Tetrahedron Lett. 1998, 39, 3287; (e) Doyle, M. P.; Yan, M. J. Org. Chem. 2002, 67, 602; (f) Aggarwal, V. K.; Alonso, E.; Bae, I.; Hynd, G.; Lydon, K. M.; Palmer, M. J.; Patel, M.; Porcelloni, M.; Richardson, J.; Stenson, R. A.; Studley, J. R.; Vasse, J.-L.; Winn, C. L. J. Am. Chem. Soc. 2003, 125, 10926; (g) Corradi, A.; Leonelli, C.; Rizzuti, A.; Rosa, R.; Veronesi, P.; Grandi, R.; Baldassari, S.; Villa, C. Molecules 2007, 12, 1482; (h) Wen, J.; Fu, Y.; Zhang, R.-Y.; Zhang, J.; Chen, S.-Y.; Yu, X.-Q. Tetrahedron 2011, 67, 9618.
The spectral data for compound 5-phenyl-1H-pyrazole 3 is in agreement with

- The spectral data for compound 5-phenyl-1H-pyrazole 3 is in agreement with the literature values. For the related reference, see: Kudo, N.; Perseghini, M.; Fu, G. C. Angew. Chem., Int. Ed. 2006, 45, 1282.
- The spectral data for compounds 4v and 4w is in agreement with the literature values. For the related reference, see: Montoya, V.; Pons, J.; Branchadellb, V.; Ros, J. Tetrahedron 2005, 61, 12377.
- 13. Erkklilä, A.; Pihko, P. M. J. Org. Chem. 2006, 71, 2538.